Kornimate/medical-research-clean huggingface dataset:
evaluation of the positron emission tomography (pet) tracer zk 6032924 in patients with multiple sclerosis compared to healthy volunteers

Conditions: Positron-Emission Tomography; Multiple Sclerosis

Summary: pet (positron emission tomography) imaging with bay85-8101 for investigation in patients with multiple sclerosis compared to healthy volunteers


Eligibility criteria:
inclusion criteria: healthy volunteers for brain imaging: * males or females, age 20 - 55 years * assessment of the brain mri as "normal (age-appropriate)" * absence of any sign of cns disease, no co-medi cation patients for brain imaging * males or females, age 20 - 55 years * patients with previously diagnosed ms, presenting with acute relapse, without any current immunomodulating therapy for ms ("drug-naïve"), or patients presenting with first clinical episode suggestive of demyelinating disease (clinically isolated syndrome, cis) * patients with previously diagnosed ms, presenting with acute relapse, receiving currently immunomodulatory therapy exclusively with interferon β * mri: \>/= 2 t2 lesions and \>/= 1 gadolinium- (gd-) enhancing lesion exclusion criteria: exclusion criteria for all healthy volunteers and patients: * pregnancy or lactation * any disease, condition, or concomitant medications that significantly compromises the function of the body systems and could result in excessive accumulation, impaired metabolism, altered excretion of the radiotracer, or might interfere with the conduct of the study or interpretation of the results * other forms of diseases with neuroinflammatory components

Keywords: multiple sclerosis diagnostic imaging neuroinflammation pet diagnosis pet tracer
thermovision-controlled lumbar sympathetic blockade in chronic limb-threatening ischemia treatment

Conditions: Chronic Limb-Threatening Ischemia

Summary: thermovision-controlled lumbar sympathetic blockade in chronic limb-threatening ischemia treatment

chronic limb-threatening ischemia (clti), the end-stage of lower extremity artery disease (lead), occurs with growing prevalence around the globe and is associated with increased healthcare costs. clti is defined by the presence of lead in combination with rest pain, gangrene, or lower limb ulceration lasting more than two weeks. despite unclear results of abdominal surgical lumbar sympathectomy, novel interventional minimally invasive fluoroscopy-guided procedures seem to be promising. a prospective interventional study will be conducted, primarily targeting patients afflicted by critical limb ischemia, with the incorporation of thermal vision control and tissue oxygen monitoring.

Eligibility criteria:
inclusion criteria: * chronic limb-threatening ischemia-patients with chronic leg pain for at least 6 months with intensity (vas \>=5) * those who (only if a signature was obtainable), or whose legal guardian,fully understood the clinical trial -details and signed the informed consent form exclusion criteria: * chronic venous insufficiency * women with positive a pregnancy tests before the trial or who planned to become pregnant within the following 3 years * other patients viewed as inappropriate by the staff * disagreement with participation in the study
a phase ii study in adult patients with moderate to severe atopic dermatitis

Conditions: Atopic Dermatitis

Summary: this proposed study is a randomized, double-blind, placebo-controlled, 3-arm parallel, multicenter phase ii study, designed to explore the efficacy and safety of shr0302 treatment for patients with moderate to severe atopic dermatitis. the study will be conducted over a 12-week treatment period. two active doses of shr0302 will be compared to placebo and improvement in atopic dermatitis will be assessed using the investigator's global score (iga)


Eligibility criteria:
inclusion criteria: * subjects between 18-75 years of age (inclusive), male or female, at the time of informed consent * moderate to severe atopic dermatitis * capable of providing a signed and dated informed consent form indicating the subject has been informed of all pertinent aspect of the study exclusion criteria: * subjects with historical or current evidence of clinically significant cardiovascular, neurological, psychiatric, renal, hepatic, immunological, gastrointestinal, urogenital, nervous system, musculoskeletal, skin, sensory, endocrine (including uncontrolled diabetes or thyroid disease) or hematological abnormalities that are uncontrolled. significant is defined as any disease that, in the opinion of the investigator, would put the safety of the subject at risk through participation, or which would affect the efficacy or safety analysis if the disease/condition exacerbated during the study * subject has a current diagnosis of other active skin disease (e.g., psoriasis or lupus erythematosus) or skin infection (bacterial, fungal, or viral) that may affect the evaluation of atopic dermatitis * subject has a severe comorbidity that may require systemic steroids therapy or other interventions or requires active frequent monitoring (e.g., unstable chronic asthma)
8-week pk/pd atorvastatin study in children and adolescents with heterozygous familial hypercholesterolemia

Conditions: Pediatric Heterozygous Hypercholesterolemia

Summary: to evaluate pharmacokinetics, pharmacodynamics, safety and tolerability of atorvastatin in children and adolescents with heterozygous familial hypercholesterolemia


Eligibility criteria:
inclusion criteria: * genetically confirmed heterozygous familial hypercholesterolemia (hefh) with ldl greater or equal 4 mmol/l at baseline exclusion criteria: * evidence or history of clinically significant diseases, homozygous familial hypercholesterolemia (fh)

Keywords: heterozygous familial hypercholesterolemia (hefh); atorvastatin; pediatric
clinical trial to evaluate the safety and immunogenicity of mumps vaccine

Conditions: Mumps

Summary: the purpose of this study is to evaluate the safety and immunogenicity of mumps vaccine in healthy infants aged 8-12months, compared with measles, mumps and rubella combined vaccine, live (mmrv).

the study is a randomized, double-blind, controlled phase ⅳ clinical trial. and 920 infants will be assigned to investigational group and controlled group in a 1:1 ratio. the investigational vaccine is manufactured by sinovac (dalian) vaccine technology co., ltd. the controlled vaccine is manufactured by shanghai institute of biological products co., ltd.

Eligibility criteria:
inclusion criteria: * healthy volunteers between 8 - 12 months old; * proven legal identity; * written consent of the guardian(s) of the volunteer exclusion criteria: * received mumps vaccine or vaccine containing mumps virus; * history of mumps; * axillary temperature \> 37.4 °c; * history of allergy to any vaccine or vaccine ingredient; * history of serious adverse reaction(s) to vaccination, such as urticaria, difficulty in breathing, angioneurotic edema, abdominal pain, etc; * autoimmune disease or immunodeficiency or immunosuppression; * congenital malformation, genetic defects, severe malnutrition; * diagnosed coagulation function abnormal (e.g., coagulation factor deficiency, coagulation disorder, or platelet abnormalities) , or obvious bruising or coagulation disorders; * severe chronic diseases (e.g., severe cardiovascular disease, liver and kidney disease beyond the control of drugs, or cancer) * severe neurological disorders (epilepsy, seizures or convulsions) or psychosis; * history of thyroidectomy, absence of spleen, functional absence of spleen, and any condition resulting from absence of spleen or splenectomy; * receipt of any of the following products: 1. any subunit vaccine or inactivated vaccine within 7 days prior to study entry; 2. any live attenuated vaccine within 28 days prior to study entry; 3. any other investigational medicine(s) or vaccine within 30 days prior to study entry; 4. blood product within 3 months prior to study entry; 5. any immunosuppressant, cytotoxic medicine, or oral corticosteroids; 6. any of the acute disease or attack of the chronic disease within 7 days; 7. pregnant in cohabitants or congenital immune diseases; 8. based on the judgment of investigator(s), there was any condition indicating that the subject should be excluded

Keywords: mumps mumps vaccine measles, mumps and rubella combined vaccine, live infants
the effects of medicaid policy interventions on racial equity in severe maternal morbidity

Conditions: Severe Maternal Morbidity; Maternal Death

Summary: the goal of this study is to learn about the effects of structural inventions, such as equity-focused medicaid polices, on severe maternal morbidity (smm) and mortality and maternal health. the main questions it aims to answer are: 1. what is the effect of medicaid healthcare quality interventions on smm? 2. what is the effect of medicaid healthcare quality interventions + doula care? 3. what are medicaid beneficiaries' experiences in receiving services and the potential impact of integration of doula services and equity practices? participants will be asked to describe experiences as a result of structural interventions and focused medicaid policies.


Eligibility criteria:
inclusion criteria: * pregnant and postpartum medicaid beneficiaries across the us qualitative: * medicaid beneficiaries who self-identify as black and/or live in pa health equity zones * doulas who provide care to medicaid beneficiaries in pennsylvania * medicaid managed care organization (mco) administrators in pennsylvania. severe maternal morbidity and mortality outcomes will be assessed in healthcare records and for these quantitative outcomes, patients will not be recruited individually exclusion criteria: -
fecal calprotectin level in patients with nosocomial diarrhea

Conditions: Diarrhea; Calprotectin

Summary: nosocomial diarrhea is a common problem.there are multiple ethiologies of nosocomial diarrhea in which can be divided into inflammatory and non inflammatory diarrhea. fecal calprotectin is a good marker to identify inflammatory diarrhea in outpatient setting; for example, differentiating inflammatory bowel disease and irritable bowel syndrome. its performance in inpatient setting has not been well established. this study aim to determine the efficacy of fecal calprotectin in distinguishing inflammatory nosocomial diarrhea from non-inflammatory nosocomial diarrhea.

this is a prospective, cross-sectional, and observational study. the patients with nosocomial diarrhea whose stool samples are sent for stool examination and clostridium difficile toxin by their treating physicians will be recruited. their leftover stool samples will be kept at - 80 c and will be measured for calprotectin level at the end of study. the patients will be treated by their treating physicians. they will be classified into 2 groups - inflammatory and non-inflammatory diarrhea. the inflammatory diarrhea will be defined if 1) positive for c. difficile toxin or 2) stool wbc more than 5/hpf or 3) inflammatory mucosa or ulceration noted on colonoscopy. the noninflammatory diarrhea will be defined if 1)negative for c. difficile toxin and 2) no wbc on stool examination and 3) dramatic response to diet adjustment or 4) no mucosal inflammation or ulceration if colonoscopy is performed the patients who do not respond to diet modification, but do not undergo colonoscopy will be excluded because the definite diagnosis cannot be made.

Eligibility criteria:
inclusion criteria: * age more than 18 hear * diarrhea more than 3 time per day after admitted in hospital more than 72 hours exclusion criteria: * intraabdominal pressure more than 12 mmhg * patient on chemotherapy with neutropenia ,anc less than 1,000/mm3 * patients whose definite diagnosis cannot be obtained

Keywords: nosocomial diarrhea fecal calprotectin
kinesthetic and visual motor imagery on cervical position sense and balance in mechanical neck pain

Conditions: Mechanical Neck Pain

Summary: to investigate the effect of kinesthetic and visual motor imagery training on cervical position sense and balance in mechanical neck pain

thirty patients with mechanical neck pain will participate in this study. the patients will randomly be divided into two equal groups; the control group which received the selected exercise program and the study group received the same exercise training program in addition to kinesthetic and visual motor imagery training, three times per week for four weeks. the evaluation methods are cervical joint position error test, neck disability index, multidirectional reach test and visual analogue scale

Eligibility criteria:
inclusion criteria: * thirty patients with mechanical neck pain, * age will range as (35:50) years old * body mass index (18:29) exclusion criteria: * difficulty to communicate or to understand program instructions * any other neurological deficits or orthopaedic abnormalities, * secondary musculoskeletal complication * cervical disc prolapses * any other cervical problem * spinal stenosis * previous spinal surgery
impact of ascorbic acid in the prevention of vancomycin induced nephrotoxicty

Conditions: Acute Kidney Injury

Summary: a randomized controlled trial aiming to investigate whether ascorbic acid has a role in preventing vancomycin induced nephrotoxicity or not in critically ill patients.

critically ill patients who have gram positive infection (mrsa) and need vancomycin will be assigned randomly into two groups. the first group will be given vancomycin intravenous only (15-20 mg/kg) every 8-12 hours , while the second group will take vancomycin intravenous (15-20 mg/kg) every 8-12 hours plus ascorbic acid 1 gram twice daily orally just before the vancomycin administration by half an hour. patients will be monitored for one week where serum creatinine, bun, urine output, trough level will be measured. acute kidney injury will be determined according to rifle criteria.

Eligibility criteria:
inclusion criteria: * adults who are critically ill and with mrsa infection suspection. exclusion criteria: 1. pregnancy or breast feeding. 2. known allergy to either vancomycin or ascorbic acid. 3. base line serum creatinine ≥2mg/dl. 4. patients receiving other nephrotoxic drug (e.g., aminoglycosides, amphotericin b, cisplatin or calcinurine inhibitors). 5. anticepated administration of contrast medium within 7 days. 6. patients suffering from some underlying diseases (e.g., cancer, hiv infection, systemic lupus erythematoses,or urinary tract stones). 7. unlikelyhood of receiving the study medications for at least 72 hours
evaluation of the impact of 3 methods of communication on the adherence of methotrexate in patients with rheumatoid arthritis

Conditions: Methotrexate; Polyarthritis; Rheumatoid

Summary: methotrexate (mtx) is the first-line treatment for rheumatoid arthritis (ra). poor adherence of this treatment decreases the control of the disease and the effectiveness of the associated treatments. the aim would be to study the observance of patients with ra and to be able to propose adequate solutions favoring patient compliance and thus the stability of the pathology. for this purpose, 3 methods of communication have been put in place to encourage adherence: usual care by the rheumatologist, sms sending or pharmaceutical maintenance.


Eligibility criteria:
inclusion criteria: * adult patients attending day hospital or consultation of rheumatology with rheumatoid polyarteritis and under treatment with mtx alone or in combination with another therapeutic, fixed dosage for at least 3 months. * consenting patient * literate french-speaking patient, * patient with a mobile phone * patient affiliated to a social security scheme exclusion criteria: * patient not managing his own treatment
asthma control: increased physical activity in young adults

Conditions: Asthma in Young Adults

Summary: investigators want to study to see if patients who participate in a physical activity intervention involving increasing daily step counts will have better mini asthma quality of life questionnaire (mini aqlq) scores at the end of the study period compared to patients that are in the control group and do not increase daily step counts. participants will be randomized into the two groups.

the control group (usual care group) of 75 patients will not participate in the intervention but will take an asthma control survey at baseline (point of enrollment into the study) and about 4-6 weeks after. the intervention group of 75 patients who will participate in the intervention of step counts and take an asthma control survey at baseline (point of enrollment into the study) and about 4-6 weeks after.

Eligibility criteria:
inclusion criteria: * patients within the geisinger south wilkes-barre primary care clinic with a diagnosis of mild to moderate asthma exclusion criteria: * patients with any medical history which would prohibit their ability to participate in increased exercise, and/or patients that are diagnosed or associated with severe asthma
to compare the efficacy and patients' satisfaction for the treatment of post cesarean pain of two protocols: oral medications in fixed time interval administration versus spinal morphine

Conditions: Post Cesarean Pain Management

Summary: cesarean deliveries are prevalent. unlike other operations, quick recovery is required for the mother to nurture the newborn child and establishing an appropriate mother-child bonding.

cesarean deliveries are prevalent. unlike other operations, quick recovery is required for the mother to nurture the newborn child and establishing an appropriate mother-child bonding. therefore, effective pain management is crucial. in this study we would like to compare between two pain relievers' administration protocols: 1. oral pain relievers' administration in fix protocol without need for patient demand 2. spinal morphine given during the spinal anesthesia in the cesarean section

Eligibility criteria:
inclusion criteria: * women that underwent cesarean section with sinal anesthesia exclusion criteria: * women who suffer from chronic pain * women using chronic pain medications * women with allergy to any drug used in the study * women underwent general anesthesia during the surgery * women who suffer from sleep apnea * women who suffer from obesity (bmi\>40) * women who suffer from severe nausea and vomiting after previous surgery * women who received perioperative magnesium * women who suffer from hypertension * women who suffer from renal failure
ease of use study of the fempulse system

Conditions: Overactive Bladder (OAB)

Summary: the objective of the study is to demonstrate that the fempulse system can be used as indicated

the objective of the study is to demonstrate that the fempulse system can be used as indicated in the patient and clinician instructions for use (ifu), as applicable.

Eligibility criteria:
key inclusion criteria: 1. females, defined as a person with a cervix, ≥21 years old, with oab symptoms, as confirmed by a physician. oab is defined by urinary urgency, usually with urinary frequency and nocturia, with or without urgency urinary incontinence with symptoms . 2. able to read, comprehend, and reliably provide informed consent and study-related information. 3. willing and able to comply with study required procedures and visits exclusion criteria: 1. any significant pain, neurologic, psychological condition or other factors, that in the investigator's judgment, might confound the protocol study assessments, and adherence to the protocol. 2. has a metal pelvic implant or an active implantable medical device, including but not limited to a cardiac pacemaker, cardioverter-defibrillator or neurostimulator 3 history of a cardiac condition including, but not limited to, clinically significant abnormal ecg or arrhythmia that may interfere with study participation as determined by investigator. 4. systemic condition or disease that may interfere with study participation or not an appropriate study candidate, as determined by study investigator.

Keywords: neuromodulation
evaluation of the impact of the modification of antibiotic susceptibility testing on antibiotic prescriptions

Conditions: Antibiotic Resistant Infection

Summary: as of 2019, the ca-sfm (comité de l'antibiogramme de la société française de microbiologie) recommends that the letter "i" or the term "intermediate" on antibiotic antibiograms. instead, it is recommended that the term "sensible à forte posologie" or "sfp". these recommendations have been in place since 21/01/2022 at nancy university hospital. pseudomonas aeruginosa is the bacterium most affected by this change, as it has a high proportion of "high dosage" antibiotics. staphylococcus aureus is the most widely isolated bacterium, and also impacted by the change in antibiotic susceptibility testing. the aim of this change in recommendations is to guarantee the efficacy of the proposed molecules. main objective evaluate the impact of the change in antibiogram recommendations in samples positive for pseudomonas aeruginosa and staphylococcus aureus on antibiotic therapy (prescribed dosage) secondary objectives * evaluate the impact of changing the way antibiograms in pseudomonas aeruginosa and staphylococcus aureus on antibiotic therapy (molecule prescribed). * evaluate the impact of changing the way antibiograms on antibiotic therapy (molecule and dosage prescribed), depending on the strain identified (pseudomonas aeruginosa or staphylococcus aureus). * describe the impact of changing antibiograms in pseudomonas aeruginosa and staphylococcus aureus on antibiotic therapy (molecule and dosage prescribed) by department.


Eligibility criteria:
inclusion criteria: * patients hospitalized with a positive monobacterial p. aeruginosa or s.aureus resulting in an antibiotic susceptibility test between 01/03/2021 and 31/08/2021 (avant period) and between 01/03/2022 and 31/08/2022 (after period) exclusion criteria: * patients from the maternity unit / the centre chirurgical emile gallé (cceg) / dialysis department (uf 1094) * patients with sample results that did not result in a prescription of antibiotics documented and duplicate samples relating to the same pathology and the same documented treatment * patient opposed to research

Keywords: antibiotic
impact of the navilas ® micropulse laser treatment for macular edema within the chu brugmann hospital macular edema

Conditions: Macular Edema

Summary: the navilas® micropulse laser can be used to treat patients with macular edema and good visual acuity, which therefore do not fall within the indications for conventional treatments by intravitreal injections. the chu brugmann hospital is the only center to own this laser in belgium.this study aims to evaluate the efficacy of this laser.


Eligibility criteria:
inclusion criteria: * diffuse macular edema without focal edema source accessible by focal laser (e.g. capillary telangiectasia) * central retinal thickness ≤ 400microns. * patient does not meet the reimbursement criteria for intra-vitreous injections(ivi) of anti-vegf (eg av\> 5/10). * ivi are contraindicated. * physician considers that it is preferable to space out the injections because of the side effects (eg. ocular disturbance during ivi, eye pain, sensation of a foreign body, spots in the visual field generating a visual gene etc.) * patient wishing to space the anti-vegf ivi. exclusion criteria: * macular edema of a different etiology than diabetic macular edema or venous thrombosis (e.g. cataract extraction, vitreomacular traction, epiretinal membrane etc.) * central retinal thickness \> 400 microns. * the eye presents a focal edematous maculopathy accessible to conventional laser.